{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:43:13Z","timestamp":1792190593333,"version":"4.4.0"},"reference-count":56,"publisher":"BMJ","issue":"9","license":[{"start":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T00:00:00Z","timestamp":1662076800000},"content-version":"unspecified","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Merck and Co. Inc., Kenilworth, NJ, USA","award":["NCT02595866"],"award-info":[{"award-number":["NCT02595866"]}]},{"name":"NCI","award":["UM1CA154967"],"award-info":[{"award-number":["UM1CA154967"]}]},{"name":"Spanish Lung Cancer Group","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"name":"DURVAST","award":["NCT03094286"],"award-info":[{"award-number":["NCT03094286"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2022,8,2]]},"published-print":{"date-parts":[[2022,9]]},"abstract":"<jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>The Food and Drug Administration recommends that people living with HIV (PWH) with a CD4+ T cell count (CD4) \u2265350 cells\/\u00b5L may be eligible for any cancer clinical trial, but there is reluctance to enter patients with lower CD4 counts into cancer studies, including immune checkpoint inhibitor (ICI) studies. Patients with relapsed or refractory cancers may have low CD4 due to prior cancer therapies, irrespective of HIV status. It is unclear how baseline CD4 prior to ICI impacts the proportion of treatment-emergent adverse events (TEAE) and whether it differs by HIV status in ICI treated patients.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We conducted a pilot retrospective cohort study of participants eligible for ICI for advanced cancers from three phase 1\/2 trials in the USA and Spain. We determined whether baseline CD4 counts differed by HIV status and whether the effect of CD4 counts on incidence of TEAE was modified by HIV status using a multivariable logistic regression model.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 122 participants, 66 (54%) were PWH who received either pembrolizumab or durvalumab and 56 (46%) were HIV-negative who received bintrafusp alfa. Median CD4 at baseline was 320 cells\/\u00b5L (IQR 210\u2013495) among PWH and 356 cells\/\u00b5L (IQR 260\u2013470) among HIV-negative participants (p=0.5). Grade 3 or worse TEAE were recorded among 7\/66 (11%) PWH compared with 7\/56 (13%) among HIV-negative participants. When adjusted for prior therapies, age, sex, and race, the effect of baseline CD4 on incidence of TEAE was not modified by HIV status for any TEAE (interaction term p=0.7), or any grade \u22653 TEAE (interaction term p=0.1).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>There was no significant difference in baseline CD4 or the proportions of any TEAE and grade \u22653 TEAE by HIV status. CD4 count thresholds for cancer clinical trials should be carefully reviewed to avoid unnecessarily excluding patients with HIV and cancer.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/jitc-2022-005128","type":"journal-article","created":{"date-parts":[[2022,9,2]],"date-time":"2022-09-02T11:00:22Z","timestamp":1662116422000},"page":"e005128","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":14,"title":["Effect of CD4+ T cell count on treatment-emergent adverse events among patients with and without HIV receiving immunotherapy for advanced cancer"],"prefix":"10.1136","volume":"10","clinical-trial-number":[{"clinical-trial-number":"nct02517398","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03427411","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03094286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03094286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03094286","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct03427411","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02595866","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Thomas A","family":"Odeny","sequence":"first","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5794-7292","authenticated-orcid":false,"given":"Kathryn","family":"Lurain","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7550-4938","authenticated-orcid":false,"given":"Julius","family":"Strauss","sequence":"additional","affiliation":[{"name":"Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven P","family":"Fling","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0044-9719","authenticated-orcid":false,"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[{"name":"Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Wright","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Martinez-Picado","sequence":"additional","affiliation":[{"name":"IrsiCaixa AIDS Research Institute, Research Institute Germans Trias i Pujol, University of Vic-Central University of Catalonia, CIBERINFECT, ICREA, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9172-0035","authenticated-orcid":false,"given":"Teresa","family":"Moran","sequence":"additional","affiliation":[{"name":"Medical Oncology Department, Catalan Institute of Oncology (ICO), Germans Trias i Pujol Hospital, Badalona-Applied Research Group in Oncology, Badalona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6569-2912","authenticated-orcid":false,"given":"James L","family":"Gulley","sequence":"additional","affiliation":[{"name":"Center for Immuno-Oncology, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3791-540X","authenticated-orcid":false,"given":"Maria","family":"Gonzalez-Cao","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Unit, Instituto Oncol\u00f3gico Dr Rosell, Dexeus University Hospital, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6959-0924","authenticated-orcid":false,"given":"Thomas S","family":"Uldrick","sequence":"additional","affiliation":[{"name":"Cancer Immunotherapy Trials Network, Fred Hutchinson Cancer Center, Seattle, Washington, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Yarchoan","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5709-4675","authenticated-orcid":false,"given":"Ramya","family":"Ramaswami","sequence":"additional","affiliation":[{"name":"HIV and AIDS Malignancy Branch, Center for Cancer Research, National Institutes of Health, Bethesda, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2022,9,2]]},"reference":[{"key":"2025100315153592000_10.9.e005128.1","doi-asserted-by":"crossref","first-page":"e240","DOI":"10.1016\/S1470-2045(21)00137-6","article-title":"The effect of non-AIDS-defining cancers on people living with HIV","volume":"22","author":"Chiao","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100315153592000_10.9.e005128.2","doi-asserted-by":"crossref","first-page":"2868","DOI":"10.1002\/cncr.32158","article-title":"Advanced stage at diagnosis and elevated mortality among US patients with cancer infected with HIV in the National cancer data base","volume":"125","author":"Coghill","year":"2019","journal-title":"Cancer"},{"key":"2025100315153592000_10.9.e005128.3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/COH.0000000000000320","article-title":"Cancer care disparities in people with HIV in the United States","volume":"12","author":"Suneja","year":"2017","journal-title":"Curr Opin HIV AIDS"},{"key":"2025100315153592000_10.9.e005128.4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.8644"},{"key":"2025100315153592000_10.9.e005128.5","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1093\/cid\/ciy373","article-title":"Disparities and determinants of cancer treatment in elderly Americans living with human immunodeficiency virus\/AIDS","volume":"67","author":"Rositch","year":"2018","journal-title":"Clin Infect Dis"},{"key":"2025100315153592000_10.9.e005128.6","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1038\/bjc.2015.301","article-title":"The exclusion of people living with HIV (PLWH) from clinical trials in lymphoma","volume":"113","author":"Venturelli","year":"2015","journal-title":"Br J Cancer"},{"key":"2025100315153592000_10.9.e005128.7","doi-asserted-by":"crossref","first-page":"e200423","DOI":"10.1001\/jamanetworkopen.2020.0423","article-title":"Estimation of the percentage of US patients with cancer who are eligible for immune checkpoint inhibitor drugs","volume":"3","author":"Haslam","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025100315153592000_10.9.e005128.8","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.21037\/atm-20-2656","article-title":"Keynote-158 study, FDA granted accelerated approval of pembrolizumab for the treatment of patients with advanced PD-L1-positive cervical cancer","volume":"8","author":"Borcoman","year":"2020","journal-title":"Ann Transl Med"},{"key":"2025100315153592000_10.9.e005128.9","doi-asserted-by":"crossref","first-page":"3838","DOI":"10.1200\/JCO.2016.68.1478","article-title":"Antitumor activity of pembrolizumab in Biomarker-Unselected patients with recurrent and\/or metastatic head and neck squamous cell carcinoma: results from the phase Ib KEYNOTE-012 expansion cohort","volume":"34","author":"Chow","year":"2016","journal-title":"J Clin Oncol"},{"key":"2025100315153592000_10.9.e005128.10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32591-7"},{"key":"2025100315153592000_10.9.e005128.11","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805131"},{"key":"2025100315153592000_10.9.e005128.12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30351-6"},{"key":"2025100315153592000_10.9.e005128.13","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100315153592000_10.9.e005128.14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31046-2"},{"key":"2025100315153592000_10.9.e005128.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1603702"},{"key":"2025100315153592000_10.9.e005128.16","doi-asserted-by":"crossref","first-page":"e1077","DOI":"10.1634\/theoncologist.2020-0184","article-title":"Fda accelerated approval of pembrolizumab for recurrent locally advanced or metastatic Merkel cell carcinoma","volume":"25","author":"Bradford","year":"2020","journal-title":"Oncologist"},{"key":"2025100315153592000_10.9.e005128.17","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/S1470-2045(21)00005-X","article-title":"Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study","volume":"22","author":"Kuruvilla","year":"2021","journal-title":"Lancet Oncol"},{"key":"2025100315153592000_10.9.e005128.18","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.72.1316"},{"key":"2025100315153592000_10.9.e005128.19","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30167-X"},{"key":"2025100315153592000_10.9.e005128.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910231"},{"key":"2025100315153592000_10.9.e005128.21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1801005"},{"key":"2025100315153592000_10.9.e005128.22","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11904-020-00525-y","article-title":"Anti-PD-1 and anti-PD-L1 monoclonal antibodies in people living with HIV and cancer","volume":"17","author":"Lurain","year":"2020","journal-title":"Curr HIV\/AIDS Rep"},{"key":"2025100315153592000_10.9.e005128.23","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju503","article-title":"Excess cancers among HIV-infected people in the United States","volume":"107","author":"Robbins","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"2025100315153592000_10.9.e005128.24","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002097","article-title":"Use of pembrolizumab with or without pomalidomide in HIV-associated non-Hodgkin's lymphoma","volume":"9","author":"Lurain","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100315153592000_10.9.e005128.25","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","article-title":"Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma","volume":"11","author":"Li","year":"2018","journal-title":"J Hematol Oncol"},{"key":"2025100315153592000_10.9.e005128.26","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-12-756841"},{"key":"2025100315153592000_10.9.e005128.27","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1001\/jamaoncol.2019.2244","article-title":"Assessment of the safety of pembrolizumab in patients with HIV and advanced cancer-a phase 1 study","volume":"5","author":"Uldrick","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100315153592000_10.9.e005128.28","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1001\/jamaoncol.2020.0465","article-title":"Assessment of the feasibility and safety of Durvalumab for treatment of solid tumors in patients with HIV-1 infection: the phase 2 DURVAST study","volume":"6","author":"Gonzalez-Cao","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100315153592000_10.9.e005128.29","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0771-1"},{"key":"2025100315153592000_10.9.e005128.30","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamaoncol.2018.6737","article-title":"Safety and efficacy of immune checkpoint inhibitor therapy in patients with HIV infection and advanced-stage cancer: a systematic review","volume":"5","author":"Cook","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100315153592000_10.9.e005128.31","doi-asserted-by":"crossref","first-page":"e2027110","DOI":"10.1001\/jamanetworkopen.2020.27110","article-title":"Assessment of cancer therapy evaluation program advocacy and inclusion rates of people living with HIV in Anti-PD1\/PDL1 clinical trials","volume":"3","author":"Reuss","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025100315153592000_10.9.e005128.32","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001664"},{"key":"2025100315153592000_10.9.e005128.33","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-86081-w","article-title":"Exclusion of patients living with HIV from cancer immune checkpoint inhibitor trials","volume":"11","author":"Vora","year":"2021","journal-title":"Sci Rep"},{"key":"2025100315153592000_10.9.e005128.34","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1200\/JCO.2017.73.7338","article-title":"Modernizing clinical trial eligibility criteria: recommendations of the American Society of clinical Oncology-Friends of cancer research HIV Working group","volume":"35","author":"Uldrick","year":"2017","journal-title":"J Clin Oncol"},{"key":"2025100315153592000_10.9.e005128.35","unstructured":"US Department of Health and Human Services Food and Drug Administration . Cancer Clinical Trial Eligibility Criteria:Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections, 2020."},{"key":"2025100315153592000_10.9.e005128.36","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1615896"},{"key":"2025100315153592000_10.9.e005128.37","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1182\/blood-2018-01-791400","article-title":"Optimizing treatment of HIV-associated lymphoma","volume":"134","author":"Noy","year":"2019","journal-title":"Blood"},{"key":"2025100315153592000_10.9.e005128.38","doi-asserted-by":"crossref","first-page":"498","DOI":"10.4103\/2141-9248.122054","article-title":"Pattern of CD4 T-lymphocyte values in cancer patients on cytotoxic therapy","volume":"3","author":"Madu","year":"2013","journal-title":"Ann Med Health Sci Res"},{"key":"2025100315153592000_10.9.e005128.39","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.e15141","article-title":"The safety and efficacy of immune-checkpoint inhibitor therapy in HIV infected cancer patients","volume":"38","author":"Myint","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2025100315153592000_10.9.e005128.40","doi-asserted-by":"crossref","first-page":"114268","DOI":"10.18632\/oncotarget.23217","article-title":"Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors","volume":"8","author":"Diehl","year":"2017","journal-title":"Oncotarget"},{"key":"2025100315153592000_10.9.e005128.41","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.618570","article-title":"Absolute lymphocyte count predicts immune-related adverse events in patients with non-small-cell lung cancer treated with nivolumab monotherapy: a multicenter retrospective study","volume":"11","author":"Egami","year":"2021","journal-title":"Front Oncol"},{"key":"2025100315153592000_10.9.e005128.42","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001395"},{"key":"2025100315153592000_10.9.e005128.43","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122089","article-title":"Enhancement of Antiviral CD8+ T-Cell Responses and Complete Remission of Metastatic Melanoma in an HIV-1-Infected Subject Treated with Pembrolizumab","volume":"8","author":"Blanch-Lombarte","year":"2019","journal-title":"J Clin Med"},{"key":"2025100315153592000_10.9.e005128.44","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.abl3836","article-title":"Pembrolizumab induces HIV latency reversal in people living with HIV and cancer on antiretroviral therapy","volume":"14","author":"Uldrick","year":"2022","journal-title":"Sci Transl Med"},{"key":"2025100315153592000_10.9.e005128.45","doi-asserted-by":"crossref","first-page":"e690","DOI":"10.1016\/S2352-3026(20)30142-3","article-title":"Car T-cell therapy for cancer and HIV through novel approaches to HIV-associated haematological malignancies","volume":"7","author":"Rust","year":"2020","journal-title":"Lancet Haematol"},{"key":"2025100315153592000_10.9.e005128.46","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.001"},{"key":"2025100315153592000_10.9.e005128.47","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ejca.2018.12.029","article-title":"Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I\/II expansion cohort","volume":"109","author":"Segal","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100315153592000_10.9.e005128.48","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ejca.2018.11.015","article-title":"Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with \u226525% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy","volume":"107","author":"Zandberg","year":"2019","journal-title":"Eur J Cancer"},{"key":"2025100315153592000_10.9.e005128.49","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1001\/jamaoncol.2018.4628","article-title":"Safety and efficacy of Durvalumab with or without tremelimumab in patients with PD-L1-Low\/Negative recurrent or metastatic HNSCC: the phase 2 CONDOR randomized clinical trial","volume":"5","author":"Siu","year":"2019","journal-title":"JAMA Oncol"},{"key":"2025100315153592000_10.9.e005128.50","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01265"},{"key":"2025100315153592000_10.9.e005128.51","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S2468-1253(21)00382-4","article-title":"Pembrolizumab for previously treated advanced anal squamous cell carcinoma: results from the non-randomised, multicohort, multicentre, phase 2 KEYNOTE-158 study","volume":"7","author":"Marabelle","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"2025100315153592000_10.9.e005128.52","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1200\/GO.21.00096","article-title":"Cancer clinical trials in Africa-An Untapped opportunity: recommendations from aortic 2019 conference special interest group in clinical trials","volume":"7","author":"Ibraheem","year":"2021","journal-title":"JCO Glob Oncol"},{"key":"2025100315153592000_10.9.e005128.53","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1200\/EDBK_100021","article-title":"Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy","volume":"39","author":"Nazha","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100315153592000_10.9.e005128.54","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.29_suppl.97","article-title":"Racial disparities in cancer clinical trials","volume":"38","author":"Khandwala","year":"2020","journal-title":"Journal of Clinical Oncology"},{"key":"2025100315153592000_10.9.e005128.55","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1200\/EDBK_323523","article-title":"Immune-Based cancer treatment: addressing disparities in access and outcomes","volume":"41","author":"Osarogiagbon","year":"2021","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100315153592000_10.9.e005128.56","unstructured":"Guidelines for the prevention and treatment of opportunistic infections adults and adolescents with HIV: recommendations from the centers for disease control and prevention, the National Institutes of health, and the HIV medicine association of the infectious diseases Society of America. Available: https:\/\/clinicalinfo.hiv.gov\/en\/guidelines\/adult-and-adolescent-opportunistic-infection\/"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2022-005128","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T22:15:47Z","timestamp":1759529747000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2022-005128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":56,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2022,9,2]]},"published-print":{"date-parts":[[2022,9]]}},"alternative-id":["10.1136\/jitc-2022-005128"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2022-005128","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9]]}}}